Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

Clinical operations teams can expect a high return on investments in AI in the next 5–10 years, according to speakers at ...

Vietnam is aiming to attract overseas investment to encourage domestic drug development through the amended 2016 Law on ...

IPA has entered a strategic partnership with Ribopro aiming to transform therapeutic antibody discovery and development.

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

Eli Lilly has announced plans to expand its domestic medicine production in the US with four new pharmaceutical manufacturing ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

RedHill has signed an exclusive licensing agreement with Hyloris for the global development and commercialisation of RHB-102 ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Grin Therapeutics’ radiprodil.